[go: up one dir, main page]

CA3190070A1 - Vaccin a souche ha pour cibles positives aux anticorps ha - Google Patents

Vaccin a souche ha pour cibles positives aux anticorps ha

Info

Publication number
CA3190070A1
CA3190070A1 CA3190070A CA3190070A CA3190070A1 CA 3190070 A1 CA3190070 A1 CA 3190070A1 CA 3190070 A CA3190070 A CA 3190070A CA 3190070 A CA3190070 A CA 3190070A CA 3190070 A1 CA3190070 A1 CA 3190070A1
Authority
CA
Canada
Prior art keywords
stem
vaccine
virus
influenza virus
recombinant vector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3190070A
Other languages
English (en)
Inventor
Martijn Alexander LANGEREIS
Iwan Verstegen
Cornelis Alexander Maria De Haan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intervet International BV
Original Assignee
Intervet International BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intervet International BV filed Critical Intervet International BV
Publication of CA3190070A1 publication Critical patent/CA3190070A1/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/11—Orthomyxoviridae, e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La présente invention concerne des vaccins contre une infection ou une maladie du virus de la grippe pour des cibles avec des anticorps préexistants contre le domaine tête de l'hémagglutinine (HA) du virus de la grippe. L'invention concerne un vecteur recombinant exprimant un polypeptide souche HA, un vaccin comprenant le vecteur ou une cellule hôte avec ledit vecteur, des utilisations du vecteur, la cellule hôte, ou le vaccin, et des procédés de réduction d'une infection ou d'une maladie du virus de la grippe. Le vecteur recombinant peut être un acide nucléique tel qu'un plasmide d'expression eucaryote ou un ARN, un virus ou une particule de réplicon (RP). La présente vaccination permet l'induction d'une réponse immunitaire précoce et efficace contre une infection ou une maladie induite par le virus de la grippe, qui n'est pas gênée par des anticorps de domaine tête anti-HA préexistants.
CA3190070A 2020-09-07 2021-09-06 Vaccin a souche ha pour cibles positives aux anticorps ha Pending CA3190070A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20194937 2020-09-07
EP20194937.7 2020-09-07
PCT/EP2021/074446 WO2022049276A1 (fr) 2020-09-07 2021-09-06 Vaccin à souche ha pour cibles positives aux anticorps ha

Publications (1)

Publication Number Publication Date
CA3190070A1 true CA3190070A1 (fr) 2022-03-10

Family

ID=72428193

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3190070A Pending CA3190070A1 (fr) 2020-09-07 2021-09-06 Vaccin a souche ha pour cibles positives aux anticorps ha

Country Status (9)

Country Link
US (1) US20240024456A1 (fr)
EP (1) EP4210740A1 (fr)
JP (1) JP2023539771A (fr)
KR (1) KR20230065321A (fr)
CN (1) CN116528893A (fr)
BR (1) BR112023004123A2 (fr)
CA (1) CA3190070A1 (fr)
MX (1) MX2023002674A (fr)
WO (1) WO2022049276A1 (fr)

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5961982A (en) 1985-09-06 1999-10-05 Syntro Corporation Recombinant herpesvirus of turkeys and uses thereof
FR2749022B1 (fr) 1996-05-23 2001-06-01 Rhone Merieux Cellules aviaires immortelles
US5672485A (en) 1996-08-13 1997-09-30 Regents Of The University Of Minnesota Immortalized cell lines for virus growth
ATE420965T1 (de) 2004-05-18 2009-01-15 Alphavax Inc Von tc-83 abgeleitete alphavirus-vektoren, partikel und verfahren
MX2008011727A (es) 2006-03-15 2008-12-10 Intervet Int Bv Vectores de virus mononegaviral recombinantes.
CA2689588C (fr) 2007-06-21 2016-08-23 Alphavax, Inc. Cassettes sans promoteur pour l'expression de proteines structurales d'alphavirus
JP2013526849A (ja) 2010-03-30 2013-06-27 モウント シナイ スクール オフ メディシネ インフルエンザウイルスワクチン及びその使用
HUE033739T2 (en) 2010-10-18 2018-01-29 Intervet Int Bv Turkey herpesvirus vector vaccine against avian influenza in poultry
CN103917239B (zh) 2011-05-27 2016-10-05 20迈德医疗私人有限公司 纳米凝胶
AU2012343981B2 (en) 2011-11-28 2017-09-07 Janssen Vaccines & Prevention B.V. Influenza virus vaccines and uses thereof
MX2017000395A (es) * 2014-07-10 2018-02-08 Janssen Vaccines & Prevention Bv Vacunas contra virus influenza y usos de las mismas.
EP3227433B1 (fr) 2014-12-04 2018-10-10 Intervet International B.V. Fibroblastes d'embryon de poulet immortalisées
AR103245A1 (es) 2014-12-24 2017-04-26 Intervet Int Bv Vacuna vectorial basada en hvt (herpes virus de los pavos) frente a nd (enfermedad de newcastle) - ibd (enfermedad de gumboro) mejorada
EP3720488A1 (fr) 2017-12-04 2020-10-14 Intervet International B.V. Vaccination avec des particules de réplicon et un adjuvant huileux
JP7448475B2 (ja) 2017-12-20 2024-03-12 インターベット インターナショナル ベー． フェー． 細胞関連アルファヘルペスウイルスワクチン用の改善された希釈液

Also Published As

Publication number Publication date
WO2022049276A1 (fr) 2022-03-10
EP4210740A1 (fr) 2023-07-19
KR20230065321A (ko) 2023-05-11
BR112023004123A2 (pt) 2023-04-04
CN116528893A (zh) 2023-08-01
US20240024456A1 (en) 2024-01-25
MX2023002674A (es) 2023-04-03
JP2023539771A (ja) 2023-09-19

Similar Documents

Publication Publication Date Title
Vincent et al. Swine influenza viruses: a North American perspective
US8288090B2 (en) Influenza vaccines
Rahn et al. Vaccines against influenza A viruses in poultry and swine: Status and future developments
JP6375329B2 (ja) ベロ細胞において増強された複製を有する高力価の組換えインフルエンザウイルス
US10905756B2 (en) Bivalent swine influenza virus vaccine
US11180737B2 (en) Generation of infectious influenza viruses from virus-like particles
CN103370079B (zh) 针对家禽中禽流感的火鸡疱疹病毒作为载体的疫苗
CN113186173B (zh) 一种基于减毒流感病毒载体的新型冠状病毒肺炎疫苗
US20190358316A1 (en) Infectious bronchitis virus vaccine using newcastle disease viral vector
CN101421302A (zh) 针对禽流感病毒的嵌合疫苗抗原
KR20150036685A (ko) 약독화된 돼지 인플루엔자 백신 및 이의 제조 방법 및 용도
US20240024456A1 (en) Ha stem vaccine for ha antibody-positive targets
EP3715459B1 (fr) Souche de vaccin de la grippe aviaire h9 qui effectue une différenciation des animaux infectés par rapport aux animaux vaccinés, et son procédé de préparation
JP7491600B2 (ja) ユニバーサルインフルエンザワクチン
KR101908905B1 (ko) 인플루엔자 바이러스의 h9 및 h5의 다중 아형에 대한 교차 면역반응을 형성하는 신규한 재조합 인플루엔자 바이러스 및 이를 포함하는 백신
Shrestha Enhancing protective efficacy of avian influenza vaccines through targeted delivery of protective antigens to chicken immune cells
US20240000920A1 (en) Recombinant vectors encoding chimeric coronavirus spike proteins and use thereof
WO2008157203A2 (fr) Procédés pour protéger des animaux de l'infection par la grippe aviaire
Guo et al. Recombinant avian metapneumovirus subtype C expressing HA protein of H9N2 avian influenza virus are stable and induce protection
KR101788236B1 (ko) 무병원성 및 고면역원성 인플루엔자 바이러스
CN116685347A (zh) 编码嵌合冠状病毒刺突蛋白的重组载体及其用途
Thapa Protective mucosal immunity elicited by intranasal DNA vaccination expressing HA1 of equine-2 influenza virus
Tully Towards the development of a universal influenza vaccine: investigating viral-vectored vaccine-induced heterosubtypic immune responses to influenza A
Aslam et al. Journal of Population Therapeutics & Clinical Pharmacology

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20230912

EEER Examination request

Effective date: 20230912